Choosing the Right Diabetic kidney disease Treatment for Type 2 Diabetes with SGLT2 Inhibitors or GLP-1s

New insights on how to individualize care for diabetic kidney disease using updated ADA guidance and trial evidence

Topline

SGLT2 inhibitors and GLP-1 receptor agonists are now both proven to reduce the progression of chronic kidney disease (CKD) in type 2 diabetes, with the FLOW trial confirming kidney benefits for semaglutide. Choosing between the two depends on individual risk factors, comorbidities, and patient goals.

Study Details

Chronic kidney disease affects up …